The employee received an aggregate of 5,330 restricted stock units (RSUs). The RSUs will vest in equal annual installments on the first four anniversaries of January 1, 2025, subject to such ...

Heart disease is one of the leading causes of death worldwide, and while lifestyle choices like diet, exercise, and smoking ...

In the trial, 20% of patients didn’t respond well to the PCSK9 inhibitor—could genetic markers be used to tailor therapy?

The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the ...

By binding to a critical 16-amino-acid sequence in PCSK9, evolocumab prevents PCSK9 ... bases in DNA that together comprise the BRCA gene. Myriad obtained a patent for the sequenced gene along ...

Detailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.

VERVE-102 is a novel, investigational gene editing medicine designed to be a single course treatment that permanently turns off the PCSK9 gene in the liver and durably reduces disease-driving low ...

For AZD5004, the company is already eyeing up opportunities to trial it alongside AstraZeneca’s approved SGLT2 inhibitor Farxiga and its oral PCSK9 inhibitor AZD0780, according to Sharon Barr ...

Second, gene variants can suggest biologic causality and provide insights into human mechanistic ... successful targets can often be retrospectively substantiated by genome-wide significant variants.